Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors

Br J Dermatol. 2018 Jul;179(1):224. doi: 10.1111/bjd.16675. Epub 2018 May 8.

Authors

L Machet^{1

2}, J Zaragoza³, A Finon³, M Garnier², H Maillard⁴, A Caille^{5

6}

Affiliations

¹ Inserm U1253, University of Tours, Tours, France.
² Department of Dermatology, Tours, France.
³ Department of Dermatology, CHR Orléans, Orléans, France.
⁴ Department of Dermatology, CH Le Mans, Le Mans, France.
⁵ PRES Centre, Val de Loire University, University of Tours, Tours, France.
⁶ INSERM CIC 1415, CHRU Tours, Tours, France.

PMID: 29660775
DOI: 10.1111/bjd.16675

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immunotherapy
Lactate Dehydrogenases
Lymphocytes
Melanoma*
Neutrophils
Nivolumab*

Substances

Nivolumab
Lactate Dehydrogenases